IP Library Granted Patent US 10,914,744
Granted Patent B2
US 10,914,744 · App. 15/111,162 · Granted Feb 9, 2021

Method and means for diagnosing and treating allergy

Inventors: Franziska Roth-Walter (Vienna, AT); Erika Jensen-Jarolim (Vienna, AT); Cristina Gomez-Casado (Getafe, ES); Araceli Diaz Perales (Madrid, ES); Luis Fernandez Pacios (Madrid, ES); Josef Singer (Kleinbaumgarten, AT)
Assignee: BIOMEDICAL INTERNATIONAL R+D GMBH
G01N33/6893A61K31/295A61K31/315A61K31/353A61K39/35A61K47/551C07K14/47G01N33/6863G01N33/92A61K39/00G01N2800/24
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,914,744
App. No.
15/111,162
Granted
Feb 9, 2021
Kind
B2
Abstract

Disclosed is a method for diagnosing allergy in a human or animal patient, wherein the level of species-specific lipocalin, especially lipocalin 2 in a human patient, is measured in a sample of said patient and wherein a lowered level of said lipocalin compared to the level of said lipocalin in the corresponding sample of a human or animal that has no allergy, is indicative of an allergy, as well as a kit for performing this method, and a kit for quality control of allergen molecules or extracts used for immunotherapy of allergy by determining its siderophore-iron ligand load and thus immunomodulatory potency. Further, lipocalin proteins for use in treatment or prevention of allergies are provided, preferably complexed with siderophore-iron ligands.

Claims (12)

1. A method of treating allergies, which comprises administering to a patient in need thereof, a therapeutically effective amount of at least one protein selected from human lipocalin 2, Alt a 1, Bet v 1, BLG, Can f 1, and Fel d 4, wherein the protein is provided together with a catechol, a catechol-derivative, and/or retinoic acid, and a metal ion selected from Fe and/or Zn.

2. The method according to claim 1 , which comprises a reduction and amelioration of allergy symptoms.

3. The method according to claim 1 , wherein the protein is administered in combination with Fe.

4. The method according to claim 1 , wherein the protein is administered together with a metal-ion complexed with a catechol, a catechol-derivative and/or retinoic acid, in a molar ratio of 0.5 to 3 to 3 to 0.5.

5. The method according to claim 1 , wherein the protein is administered using systemic immunotherapy, sublingual immunotherapy or oral immunotherapy.

6. The method according to claim 1 , wherein the protein is administered intramuscularly, intranasally, intralymphatically or through mucosal surfaces or via the subcutaneous route.

7. The method according to claim 1 , wherein the protein is administered at a concentration of 0.1 to 600 μg/ml.

8. The method according to claim 1 , wherein the protein is administered together with a metal-ion complexed with a catechol, a catechol-derivative and/or retinoic acid, in a molar ratio of 1 to 3 to 3 to 1.

9. The method according to claim 1 , wherein the protein is administered together with a metal-ion complexed with a catechol, a catechol-derivative and/or retinoic acid, in a molar ratio of 2.0 to 3 to 3 to 2.

10. The method according to claim 1 , wherein the protein is administered at a concentration of 0.5 to 100 μg/ml.

11. The method according to claim 1 , wherein the protein is administered at a concentration of 1 to 50 μg/ml.

12. A method of treating allergies, which comprises administering to a patient in need thereof, a therapeutically effective amount of BLG provided together with a catechol, a catechol-derivative, and/or retinoic acid, and a metal ion selected from Fe and/or Zn.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 14, 2017
From: ROTH-WALTER, FRANZISKA; JENSEN-JAROLIM, ERIKA; GOMEZ-CASADO, CRISTINA; DIAZ PERALES, ARACELI; FERNANDEZ PACIOS, LUIS; SINGER, JOSEF
To: BIOMEDICAL INTERNATIONAL R+D GMBH
Reel/Frame 041572/0870 →
Priority Claims (1)
EP 14150965 · Jan 13, 2014 · regional
Continuity (1)
Related Publication 20160334418A1 · Nov 17, 2016